# US 2024/0002904 A1 · Targeted enrichment using nanopore selective sequencing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002904 A1
- Document ID: US20240002904A1
- Status: Published application
- Kind: A1
- Application number: 18/038,381
- Filed: 2021-11-24
- Published: 2024-01-04
- Earliest claimed: 2020-11-24
- Assignees: Keygene N.V.
- Applicants: Keygene N.V.
- Inventors: Theodorus Frank Maria ROELOFS; René Cornelis Josephus HOGERS
- Web page: https://patentgrep.com/patent/US20240002904A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The current invention pertains to a method for sequencing of a target nucleic acid fragment from a nucleic acid sample, comprising the steps of cleaving the nucleic acid sample with a first and a second RNA guided or DNA guided endonuclease complex, preferably a first and a second gRNA-CAS complex, thereby generating the target nucleic acid fragment and at least one non-target nucleic acid fragment. The generated fragments are subsequently contacted with an exonuclease, wherein the exonuclease digests only the non-target nucleic acid fragments. Subsequently said target nucleic acid fragment is sequenced using nanopore selective sequencing. The invention further pertains to the use of the enriched target nucleic acid fragments for nanopore selective sequencing the target nucleic acid fragment.

## Claims

### Claim 1

A method for sequencing of a target nucleic acid fragment from a sample comprising a nucleic acid molecule, wherein the target nucleic acid fragment comprises a sequence of interest, and wherein the method comprises the steps of:
a) providing the sample comprising the nucleic acid molecule, wherein the nucleic acid molecule comprises the sequence of interest;
b) cleaving the nucleic acid molecule with at least a first and a second gRNA-CAS complex, thereby generating the target nucleic acid fragment comprising the sequence of interest that is protected against exonuclease cleavage, and at least one non-target nucleic acid fragment;
c) contacting the cleaved nucleic acid molecules obtained in step b) with an exonuclease and allowing the exonuclease to digest the at least one non-target nucleic acid fragment;
d) optionally purifying the target nucleic acid fragment comprising the sequence of interest from the digest obtained in step c); and
e) sequencing the (non-digested and optionally purified) target nucleic acid fragment by nanopore selective sequencing.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method does not comprise a further step of protecting the target nucleic acid fragment, or the ends of the target nucleic acid fragment, prior to exonuclease digestion in step c).

### Claim 3 (depends on 1)

The method according to claim 1, wherein at least one of
i) step b) is performed by incubating the first and second gRNA-CAS complex and the nucleic acid molecule together for about 1 min to about 18 hours, at about 10-90° C.; and
ii) step c) is performed by incubating the cleaved nucleic acid molecule with the exonuclease for about 1 minute to about 12 hours, at about 10-90° C.

### Claim 4 (depends on 1)

The method according to claim 1, wherein at least one of the first and second gRNA-CAS complex comprises a Cas9 protein.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the at least one of the first and second gRNA-CAS complex comprises a sgRNA.

### Claim 6 (depends on 1)

The method according to claim 1, wherein at least one of the first and second gRNA-CAS complex comprises a crRNA and a tracrRNA as separate molecules.

### Claim 7 (depends on 1)

The method according to claim 1, wherein at least one of the first and second gRNA-CAS complex is capable of inducing a DSB.

### Claim 8 (depends on 1)

The method according to claim 1, wherein both the first and the second gRNA-CAS complex are capable of inducing a DSB.

### Claim 9 (depends on 1)

The method according to claim 1, wherein in step b) at least one of the first and second gRNA-CAS complex nicks one strand of the nucleic acid molecule, and wherein the nucleic acid molecule is contacted with at least a third gRNA-CAS complex that nicks the complement strand at substantially the complementary position of the position nicked by said first or second gRNA-CAS complex.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the method comprises a step of adapter ligation prior to sequencing step e.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the adapters are sequence adapters.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the method is performed in parallel for multiple nucleic acid samples.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the nucleic acid molecule is genomic DNA.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the nucleic acid molecule is a nucleic acid molecule obtainable from a plant, animal, human or microorganism.

### Claim 15 (depends on 1)

A kit of parts for enrichment of a target nucleic acid fragment from a nucleic acid molecule comprising:
at least a first and second gRNA-CAS complex as defined in claim 1;
an exonuclease; and
reagents for nanopore sequencing.

### Claim 16

(canceled)

### Claim 17 (depends on 3)

The method of claim 3, wherein step b) is performed for about 60 minutes.

### Claim 18 (depends on 3)

The method of claim 3, wherein step b) and/or step c) is performed at about 37° C.

### Claim 19 (depends on 3)

The method of claim 3, wherein step c) is performed for about 30 minutes.

### Claim 20 (depends on 10)

The method of claim 10, wherein the step of adapter ligation is following contacting step c) or optionally purifying step d).
